New antibody SHR-1707 tested in early Alzheimer's – safety first
NCT ID NCT05681819
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an experimental drug called SHR-1707 in 33 people with mild memory problems or mild Alzheimer's disease. The drug is an antibody given through a vein, designed to target and clear amyloid plaques in the brain. The main goal was to check safety and side effects, while also measuring changes in brain amyloid levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-1707 (an experimental antibody given intravenously)
What this could lead to
If successful, this could point toward a treatment that slows Alzheimer's by clearing amyloid plaques from the brain.
What could go wrong
This is a very early Phase 1 safety study with only 33 people. It is not designed to prove the drug works, and many early Alzheimer's drugs fail in later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital Of USTC
Hefei, Anhui, 230001, China